Somatostatin analogs: does pharmacology impact antitumor efficacy?

Highlights • Novel multireceptor somatostatin analogs may putatively present higher antitumor activities. • Biased agonism indicates that different somatostatin analogs cannot be considered as simple mimics of the native somatostatins. • Pharmacologic differences in somatostatin analogs need to be taken into account for optimal use of the somatostatin analogs in the clinic.